Pfizer Global Research and Development, Drug Safety Research and Development, Groton, Connecticut, USA.
Environ Mol Mutagen. 2011 Dec;52(9):685-9. doi: 10.1002/em.20687. Epub 2011 Oct 4.
The Health and Environmental Sciences Institute (HESI), a global branch of the International Life Sciences Institute (ILSI), initiated a project committee entitled "Relevance and Follow-up of Positive Results from In Vitro Genetic Toxicity Testing (IVGT)" with the overall objective of improving the scientific basis for the interpretation of results from genetic toxicology testing. The IVGT committee has also recognized the need to develop follow-up strategies for determining the relevance of in vitro test results to human health, and moving genetic toxicology testing from the sole purpose of hazard identification toward a more quantitative risk assessment approach. In this context, a group of experts evaluated the potential utility of the emerging in vivo mutational assessment model commonly known as the Pig-a gene mutation assay to follow-up positive in vitro genetic toxicology findings and to generate robust dose-response data for quantitative assessment of the in vivo mutagenicity. The IVGT experts participating in this effort represented academia, industry, and government agencies from across the globe and addressed such issues as the optimal sample size and experimental design for generating robust dose-response data. This expert group concluded that the emerging Pig-a gene mutation assay holds great promise as an in vivo mutagenicity assay, either as a stand-alone study or integrated into repeat-dose toxicology studies, and therefore supports further validation of the model.
健康与环境科学研究所(HESI)是国际生命科学学会(ILSI)的一个全球性分支机构,它发起了一个名为“体外遗传毒性测试(IVGT)阳性结果的相关性和后续行动”的项目委员会,其总体目标是改善遗传毒理学测试结果解释的科学基础。IVGT 委员会还认识到有必要制定后续策略,以确定体外测试结果与人类健康的相关性,并将遗传毒理学测试从仅用于识别危害的目的转向更定量的风险评估方法。在这种情况下,一组专家评估了新兴的体内突变评估模型(通常称为 Pig-a 基因突变检测)的潜在效用,以跟踪体外遗传毒性测试的阳性结果,并生成用于定量评估体内致突变性的稳健剂量反应数据。参与这项工作的 IVGT 专家代表了来自全球的学术界、工业界和政府机构,解决了生成稳健剂量反应数据的最佳样本量和实验设计等问题。专家组得出结论,新兴的 Pig-a 基因突变检测作为一种体内致突变性检测方法具有很大的潜力,可以作为独立的研究,也可以整合到重复剂量毒理学研究中,因此支持进一步验证该模型。